Alterations in the gut microbiome and its metabolites are associated with the immune response to mucosal immunization with Lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 spike epitopes in mice
- PMID: 37705931
- PMCID: PMC10495993
- DOI: 10.3389/fcimb.2023.1242681
Alterations in the gut microbiome and its metabolites are associated with the immune response to mucosal immunization with Lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 spike epitopes in mice
Abstract
Lactic acid bacteria (LAB) expressing foreign antigens have great potential as mucosal vaccines. Our previous study reported that recombinant Lactiplantibacillus plantarum SK156 displaying SARS-CoV-2 spike S1 epitopes elicited humoral and cell-mediated immune responses in mice. Here, we further examined the effect of the LAB-based mucosal vaccine on gut microbiome composition and function, and gut microbiota-derived metabolites. Forty-nine (49) female BALB/c mice were orally administered L. plantarum SK156-displaying SARS-CoV-2 spike S1 epitopes thrice (at 14-day intervals). Mucosal immunization considerably altered the gut microbiome of mice by enriching the abundance of beneficial gut bacteria, such as Muribaculaceae, Mucispirillum, Ruminococcaceae, Alistipes, Roseburia, and Clostridia vadinBB60. Moreover, the predicted function of the gut microbiome showed increased metabolic pathways for amino acids, energy, carbohydrates, cofactors, and vitamins. The fecal concentration of short-chain fatty acids, especially butyrate, was also altered by mucosal immunization. Notably, alterations in gut microbiome composition, function, and butyrate levels were positively associated with the immune response to the vaccine. Our results suggest that the gut microbiome and its metabolites may have influenced the immunogenicity of the LAB-based SARS-CoV-2 vaccine.
Keywords: COVID-19; SARS-CoV-2; butyrate; gut microbiome; lactic acid bacteria; mucosal vaccine.
Copyright © 2023 Hwang, Vasquez, Song, Engstrand, Valeriano and Kang.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures



Similar articles
-
Oral Immunisation With Non-GMO Surface Displayed SARS-CoV-2 Spike Epitopes on Bacteria-Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice.Microb Biotechnol. 2025 Jan;18(1):e70073. doi: 10.1111/1751-7915.70073. Microb Biotechnol. 2025. PMID: 39797809 Free PMC article.
-
Mucosal immunization with lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice.Microb Cell Fact. 2023 May 9;22(1):96. doi: 10.1186/s12934-023-02100-7. Microb Cell Fact. 2023. PMID: 37161468 Free PMC article.
-
Exploring the associations between gut microbiota composition and SARS-CoV-2 inactivated vaccine response in mice with type 2 diabetes mellitus.mSphere. 2024 Sep 25;9(9):e0038024. doi: 10.1128/msphere.00380-24. Epub 2024 Aug 27. mSphere. 2024. PMID: 39189780 Free PMC article.
-
Lactiplantibacillus plantarum as a Potential Adjuvant and Delivery System for the Development of SARS-CoV-2 Oral Vaccines.Microorganisms. 2021 Mar 26;9(4):683. doi: 10.3390/microorganisms9040683. Microorganisms. 2021. PMID: 33810287 Free PMC article. Review.
-
The Role of Mucosal Immunity and Recombinant Probiotics in SARS-CoV2 Vaccine Development.Probiotics Antimicrob Proteins. 2021 Oct;13(5):1239-1253. doi: 10.1007/s12602-021-09773-9. Epub 2021 Mar 26. Probiotics Antimicrob Proteins. 2021. PMID: 33770348 Free PMC article. Review.
Cited by
-
Alterations in microbiota of patients with COVID-19: implications for therapeutic interventions.MedComm (2020). 2024 Mar 15;5(4):e513. doi: 10.1002/mco2.513. eCollection 2024 Apr. MedComm (2020). 2024. PMID: 38495122 Free PMC article. Review.
-
Unraveling intestinal microbiota's dominance in polycystic ovary syndrome pathogenesis over vaginal microbiota.Front Cell Infect Microbiol. 2024 Mar 28;14:1364097. doi: 10.3389/fcimb.2024.1364097. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38606298 Free PMC article.
-
Hidden Partner of Immunity: Microbiome as an Innovative Companion in Immunotherapy.Int J Mol Sci. 2025 Jan 20;26(2):856. doi: 10.3390/ijms26020856. Int J Mol Sci. 2025. PMID: 39859572 Free PMC article. Review.
-
Characterization of Gut Microbiota in Rats and Rhesus Monkeys After Methamphetamine Self-administration.Mol Neurobiol. 2025 Jan;62(1):861-870. doi: 10.1007/s12035-024-04318-x. Epub 2024 Jun 26. Mol Neurobiol. 2025. PMID: 38922485
-
Oral Immunisation With Non-GMO Surface Displayed SARS-CoV-2 Spike Epitopes on Bacteria-Like Particles Provokes Robust Humoral and Cellular Immune Responses, and Modulated the Gut Microbiome in Mice.Microb Biotechnol. 2025 Jan;18(1):e70073. doi: 10.1111/1751-7915.70073. Microb Biotechnol. 2025. PMID: 39797809 Free PMC article.
References
-
- Alexander J. L., Mullish B. H., Danckert N. P., Liu Z., Olbei M. L., Saifuddin A., et al. (2023). The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients. eBioMedicine 88, 104430. doi: 10.1016/j.ebiom.2022.104430 - DOI - PMC - PubMed
-
- Alharbi K. S., Singh Y., Hassan almalki W., Rawat S., Afzal O., Alfawaz Altamimi A. S., et al. (2022). Gut Microbiota Disruption in COVID-19 or Post-COVID Illness Association with severity biomarkers: A Possible Role of Pre/Pro-biotics in manipulating microflora. Chem. Biol. Interact. 358, 109898. doi: 10.1016/j.cbi.2022.109898 - DOI - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous